Dexmedetomidine	dexmedetomidine	O	O
and	and	O	O
cardiac	cardiac	O	O
protection	protection	O	O
for	for	O	O
non-cardiac	non-cardiac	O	O
surgery	surgery	O	O
:	:	O	O
a	a	O	O
meta-analysis	meta-analysis	O	O
of	of	O	O
randomised	randomised	O	O
controlled	controlled	O	O
trials	trials	O	O
.	.	O	O

We	we	O	O
conducted	conducted	O	O
a	a	O	O
systematic	systematic	O	O
review	review	O	O
of	of	O	O
the	the	O	O
effects	effects	O	O
of	of	O	O
dexmedetomidine	dexmedetomidine	O	O
on	on	O	O
cardiac	cardiac	O	O
outcomes	outcomes	O	O
following	following	O	O
non-cardiac	non-cardiac	O	O
surgery	surgery	O	O
.	.	O	O

We	we	O	O
included	included	O	O
prospective	prospective	O	O
,	,	O	O
randomised	randomised	O	O
peri-operative	peri-operative	O	O
studies	studies	O	O
of	of	O	O
dexmedetomidine	dexmedetomidine	O	O
that	that	O	O
reported	reported	O	O
mortality	mortality	O	O
,	,	O	O
cardiac	cardiac	O	O
morbidity	morbidity	O	O
or	or	O	O
adverse	adverse	O	O
drug	drug	O	O
events	events	O	O
.	.	O	O

A	a	O	O
PubMed	pubmed	O	O
Central	central	O	O
and	and	O	O
EMBASE	embase	O	O
search	search	O	O
was	was	O	O
conducted	conducted	O	O
up	up	O	O
to	to	O	O
July	july	O	O
2007	2007	O	O
.	.	O	O

The	the	O	O
reference	reference	O	O
lists	lists	O	O
of	of	O	O
identified	identified	O	O
papers	papers	O	O
were	were	O	O
examined	examined	O	O
for	for	O	O
further	further	O	O
trials	trials	O	O
.	.	O	O

Of	of	O	O
425	425	O	O
studies	studies	O	O
identified	identified	O	O
,	,	O	O
20	20	O	O
were	were	O	O
included	included	O	O
in	in	O	O
the	the	O	O
meta-analysis	meta-analysis	O	O
(	(	O	O
840	840	O	O
patients	patients	O	O
)	)	O	O
.	.	O	O

Dexmedetomidine	dexmedetomidine	O	O
was	was	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
trend	trend	O	O
towards	towards	O	O
improved	improved	O	O
cardiac	cardiac	O	O
outcomes	outcomes	O	O
;	;	O	O
all-cause	all-cause	O	O
mortality	mortality	O	O
(	(	O	O
OR	or	O	O
0.27	0.27	O	O
,	,	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
0.01	0.01	O	O
-	-	O	O
7.13	7.13	O	O
,	,	O	O
p	p	O	O
=	=	O	O
0.44	0.44	O	O
)	)	O	O
,	,	O	O
non-fatal	non-fatal	O	O
myocardial	myocardial	O	B_disease
infarction	infarction	O	S_disease
(	(	O	O
OR	or	O	O
0.26	0.26	O	O
,	,	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
0.04	0.04	O	O
-	-	O	O
1.60	1.60	O	O
,	,	O	O
p	p	O	O
=	=	O	O
0.14	0.14	O	O
)	)	O	O
,	,	O	O
and	and	O	O
myocardial	myocardial	O	O
ischaemia	ischaemia	O	O
(	(	O	O
OR	or	O	O
0.65	0.65	O	O
,	,	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
0.26	0.26	O	O
-	-	O	O
1.63	1.63	O	O
,	,	O	O
p	p	O	O
=	=	O	O
0.36	0.36	O	O
)	)	O	O
.	.	O	O

Peri-operative	peri-operative	O	O
hypotension	hypotension	O	S_disease
(	(	O	O
26	26	O	O
%	%	O	O
,	,	O	O
OR	or	O	O
3.80	3.80	O	O
,	,	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
1.91	1.91	O	O
-	-	O	O
7.54	7.54	O	O
,	,	O	O
p	p	O	O
=	=	O	O
0.0001	0.0001	O	O
)	)	O	O
and	and	O	O
bradycardia	bradycardia	O	S_disease
(	(	O	O
17	17	O	O
%	%	O	O
,	,	O	O
OR	or	O	O
5.45	5.45	O	O
,	,	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
2.98	2.98	O	O
-	-	O	O
9.95	9.95	O	O
,	,	O	O
p	p	O	O
<	<	O	O
0.00001	0.00001	O	O
)	)	O	O
were	were	O	O
significantly	significantly	O	O
increased	increased	O	O
.	.	O	O

An	an	O	O
anticholinergic	anticholinergic	O	O
did	did	O	O
not	not	O	O
reduce	reduce	O	O
the	the	O	O
incidence	incidence	O	O
of	of	O	O
bradycardia	bradycardia	O	S_disease
(	(	O	O
p	p	O	O
=	=	O	O
0.43	0.43	O	O
)	)	O	O
.	.	O	O

A	a	O	O
randomised	randomised	O	O
placebo-controlled	placebo-controlled	O	O
trial	trial	O	O
of	of	O	O
dexmedetomidine	dexmedetomidine	O	O
is	is	O	O
warranted	warranted	O	O
.	.	O	O

